Skip to content

Comparison of Two Medication Adherence Strategies to Improve Asthma Treatment Adherence

Individualized Interventions to Improve Asthma Adherence

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00115323
Enrollment
397
Registered
2005-06-22
Start date
2005-05-31
Completion date
2010-03-31
Last updated
2013-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Lung Diseases

Brief summary

This is a randomized, controlled study that will compare two medication adherence strategies in adults with moderate or severe persistent asthma as a method for improving or maintaining treatment adherence.

Detailed description

Low-income minority adults have excessively high rates of morbidity from asthma. Poor medication adherence has been documented in these individuals and contributes to the high morbidity level. This study will compare a Problem Solving intervention with an Attention Control intervention to improve and sustain asthma self-management in a clinical setting. This study will include strategies to address contextual factors related to adherence. Participants will be recruited from clinics that serve minority and low-income individuals.

Interventions

BEHAVIORALProblem Solving

Problem solving intervention

BEHAVIORALAttention Control

Attention control intervention

Sponsors

National Heart, Lung, and Blood Institute (NHLBI)
CollaboratorNIH
University of Pennsylvania
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 90 Years
Healthy volunteers
No

Inclusion criteria

* Receiving treatment for asthma at one of the participating clinics * Moderate or severe persistent asthma according to the NHLBI Guidelines * Current use of prescribed inhaled corticosteroids * Evidence of reversible airflow obstruction, as indicated by the following two criteria: 1. FEV1pp AND less than 80% at the time of study entry or within the 3 years prior to study entry 2. An increase of greater than 15% and 200ml in FEV1 with asthma treatment over the last 3 years (if there is no record of such improvement, participants will be evaluated via spirometry pre- and post-bronchodilator at the first study visit. An increase in FEV1 or FVC greater than 12% and 200 ml in FEV1 30 minutes following albuterol administration will represent evidence of reversible airflow obstruction. If a spirometer is not immediately available, participants may be evaluated using a peak flow meter, which reports a PEF. A PEFpp less than 80% and an improvement of at least 60 L per minute after the administration of albuterol will represent evidence of reversible airflow obstruction) * Has a functional telephone or mobile phone

Exclusion criteria

* Significant lung or cardiac disease (other than hypertension) * Psychiatric illness, such as mania or schizophrenia, that may make it impossible to understand or carry out the Problem Solving intervention

Design outcomes

Primary

MeasureTime frame
Adherence to prescribed inhaled steroid regimenMeasured at Week 26

Secondary

MeasureTime frame
FEV1Measured at Week 26
Quality of life factorsMeasured at Week 26

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026